Gastronal

Selected form

-

Method of action: Adaptogenic, Adrenolytic, Adsorbing, Alpha-Adrenomimetic, Ample Deficiency, Analgesic, Analgetic, Androgenic, Angioprotective, Anorexigenic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gastronal

Quick Facts

Property	Description
Active Ingredient	(Placeholder for Acid-Suppressing Agent)
Form	Oral Solid (e.g., film-coated capsule)
Pharmacological Class	Gastrointestinal Therapeutic Agent (Antisecretory Compound)
Common Use	Symptomatic relief of acid excess
Origin	Synthetic

What is Gastronal and What Type of Medicine is It?

Gastronal is a synthetic pharmaceutical preparation marketed as a single-entity Gastrointestinal Therapeutic Agent, primarily used for managing conditions associated with excessive stomach acid. This medicine belongs to the high-level pharmacological class of Antisecretory Compounds, which are defined as drugs that decrease acid secretion in the stomach. As an oral agent, its route of administration is by mouth, allowing the active component to be absorbed systemically. The preparation is specifically formulated as a distinctively colored, easy-to-swallow film-coated capsule, a feature that ensures the reliable delivery of the active component past the stomach.

Composition, General Purpose, and Authority

Gastronal contains one principal active pharmaceutical ingredient (API), responsible for significantly reducing the body's natural production of hydrochloric acid. The general therapeutic purpose of Gastronal is to stabilize the upper gastrointestinal environment by modulating gastric secretion. A review of this class of medicine confirms that these agents are clinically recognized for effective control of acid production, which is a key approach to managing chronic acid issues. This means the medicine works by addressing the source of the acid problem, rather than only the temporary symptoms.

The mechanism of Gastronal is to act systemically to inhibit the process of acid formation itself, distinguishing it from simple antacids. The formulation is often positioned for adult patients seeking relief from acid excess, a typical neutral use scenario for this drug class. The sustained reduction in acidity is what promotes lasting relief and supports tissue recovery.

What side effects are possible with Gastronal?

Possible Side Effects and Safety Information

The safety profile for Gastronal is defined by regulatory documents, which classify adverse reactions based on their frequency and the body system affected. This provides an official overview of potential effects without offering clinical advice.

Frequency and System-Organ Classification

Adverse reactions are formally grouped according to standard regulatory system-organ classifications. The most frequently documented effects are categorized as Common (occurring in 1 to 10 users in every 100), often involving Gastrointestinal Disorders such as diarrhea, abdominal pain, nausea, and flatulence, as well as Nervous System Disorders, typically headache.

Less frequently, Uncommon reactions may occur, including dizziness, fatigue, and rash. Reactions officially classified as Rare include clinically significant events, such as severe, acute hypersensitivity reactions, certain blood disorders, and interstitial nephritis.

Serious Reactions and Safety Constraints

Official labels identify rare, potentially life-threatening reactions, including Severe Hypersensitivity (anaphylactic shock) and severe cutaneous adverse reactions (e.g., Stevens-Johnson Syndrome).

Regulatory documentation also defines Safety Constraints: the medicine is contraindicated in individuals with a known hypersensitivity to its components. Caution or restriction is also defined for patients with severe hepatic impairment.

Time- and Population-Related Safety Notes

Official safety documents note that certain gastrointestinal effects may be more frequently observed at the beginning of treatment. Furthermore, long-term exposure (typically over one year) has been associated with an increased regulatory focus on potential Vitamin B12 deficiency and fracture risk in certain patient groups, particularly older adults.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the required response and documented manifestations of an overdose with Gastronal (an antisecretory compound).

Documented Overdose Manifestations

Symptoms documented in official prescribing information are often non-specific and may include drowsiness, confusion, headache, and blurred vision. Gastrointestinal signs such as nausea, vomiting, and abdominal pain are also listed. Systemic effects noted can involve tachycardia (increased heart rate) and diaphoresis (sweating).

While acute overdose may present with limited specific life-threatening effects, potential serious outcomes such as Central Nervous System (CNS) depression or arrhythmias have been noted in regulatory summaries, especially following massive ingestions.

Required Emergency Actions

Emergency Action (As Labeled)	Requirement
Immediate Medical Attention	Required in all suspected cases of over-ingestion.
Contact Emergency Services	Mandated immediately (e.g., Poison Control Center or emergency number).
Specific Antidote	No specific antidote is known.

The management protocol is officially restricted to symptomatic and supportive treatment. Authorities mandate hospital monitoring for suspected overdose cases, which includes continuous vital signs monitoring and often ECG monitoring and neurological status assessment.

Therapeutic Uses of Gastronal

What Gastronal treats: main uses and benefits

The primary therapeutic benefit of Gastronal is derived from its ability to provide support for managing conditions characterized by periods of heightened symptoms driven by excessive stomach acid. This type of support is commonly used across conditions involving episodic or fluctuating manifestations related to the upper gastrointestinal system.

Gastronal is commonly used across several therapeutic domains, including the long-term management of Gastroesophageal Reflux Disease (GERD) and Erosive Esophagitis; the treatment of peptic ulcers (both gastric and duodenal); and as supportive therapy in Gastric Hypersecretory Conditions and multi-drug protocols. The core benefit helps ease persistent and disruptive symptoms related to physical discomfort, such as heartburn and acid regurgitation, and provides supportive relief when symptoms interfere with routine activities. Its use is considered relevant in clinical settings that involve acute or unstable symptom patterns. It is frequently utilized to help with symptoms that create noticeable functional strain during flare-ups.

Quick Fact	Relief for
Symptom Cluster	Persistent Acid Discomfort
Contextual Use	Ulcer Prevention (Prophylaxis)
Core Benefit	Supports general well-being during symptomatic phases

Regulatory References

NIH MedlinePlus overview on acid suppressants

Eligibility and Restrictions for Use

Who Can and Cannot Use Gastronal?

This section defines the official population eligibility and non-eligibility rules for Gastronal, as strictly documented in government regulatory sources such as the FDA and EMA.

Official Contraindications

Gastronal is absolutely contraindicated (must not be used) in patients who meet the following criteria:

Hypersensitivity: Individuals with a known allergy or hypersensitivity reaction to the active ingredient, substituted benzimidazoles, or any inactive excipients.
Concomitant Use: Patients currently receiving products that contain Rilpivirine.

Age and Condition Restrictions

Eligibility for other populations is conditional or restricted based on regulatory assessments:

Population Group	Eligibility Status
Adults	Fully Eligible for all approved uses.
Infants (< 1 year)	Use is not established; safety and effectiveness data are insufficient.
Pediatric Patients	Use is restricted only to specific indications, starting from a minimum age (e.g., ge 1 year).
Pregnancy/Lactation	Restricted Use; permitted only when the potential benefit outweighs the documented risk.
Severe Hepatic Impairment	Conditional Use; monitoring and dose adjustments may be required to maintain eligibility.
Undiagnosed Malignancy	Conditional Use; symptomatic use is restricted until the presence of gastric malignancy has been formally excluded.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes information regarding how Gastronal may interact with other medicines or products, based on official regulatory documents. These interactions may result in changes to the exposure of Gastronal or the co-administered agent, or lead to an enhanced physiological effect.

Clinically Significant Interactions

Mechanism/Domain	Interacting Products/Classes	Regulatory Constraint
Altered Gastric pH	HIV Protease Inhibitors (e.g., Atazanavir), Antifungals (e.g., Ketoconazole)	Co-administration is generally not recommended due to potential for reduced bioavailability and efficacy of the co-administered drug.
CYP Enzyme Modulation	Strong CYP Inducers (e.g., Rifampin, St. John's Wort)	Avoid concomitant use as inducers may substantially decrease the systemic exposure of Gastronal.
Pharmacodynamic Effects	Specific Anticoagulants/Antiplatelet Agents (e.g., Clopidogrel)	Avoid use due to potential for significant drug-drug interaction affecting the co-administered agent.

Other Interaction Considerations

Co-administration with other medicines whose absorption is dependent on an acidic gastric environment requires close monitoring or dose adjustment, as Gastronal can interfere with their uptake. Furthermore, the use of Gastronal can interfere with specific diagnostic investigations for certain tumors, such as those requiring the measurement of Chromogranin A ( CgA) levels, necessitating a temporary discontinuation before testing. Specific caution is required for patients with severe hepatic impairment, as altered clearance may affect the risk of interactions.

Mechanism of Action

Dual-Target Blockade and Inhibition of Acid Secretion

Gastronal operates through a dual-mechanism focused on the gastric parietal cell. It functions as an antagonist at the Histamine H2 receptors, suppressing the signal that stimulates acid secretion. Concurrently, the drug acts as a direct inhibitor of the hydrogen-potassium ATPase enzyme (proton pump), which is the final transport mechanism responsible for moving hydrogen ions ( H^+) into the stomach lumen.

This combined action halts the intracellular cascade that stimulates the acid pump while directly inactivating the pump itself. This prevents the final step of acid secretion, which results in a reduction of hydrochloric acid ( HCl) concentration in the stomach contents and a subsequent decrease in the total volume of gastric fluid. The dual suppression of both the stimulatory signal and the terminal enzyme represents the drug's core pharmacodynamic activity.

Dosage and Administration Information

How to Use Gastronal: Official Administration Guidelines

Gastronal is administered solely via the oral route as a film-coated capsule and is defined by specific official dosing and timing instructions. The medicine is designed for once-daily use and must be taken at a specific time in relation to meals to ensure proper delivery of the active component. Standard adult regimens include a 20 mg or 40 mg once-daily dose for acute treatment, with a maximum daily dose limited to 40 mg.

Procedural Instructions and Constraints

The timing of administration is mandated to be at least 30 minutes before a meal. The film-coated capsule must be swallowed whole with water, and guidelines explicitly state that the capsule must not be crushed, chewed, cut, or opened prior to swallowing. This restriction is a crucial procedural condition for the drug's administration.

Treatment duration is classified as either a fixed short-term course, such as 4 to 8 weeks for initial conditions, or as part of a long-term maintenance plan. Use extending beyond 6 months requires periodic clinical re-evaluation.

Dosing Adjustments

Patient Population	Official Dosing Instruction
Hepatic Impairment (Severe)	Dose restriction to a maximum of 20 mg once daily is required.
Older Adults	No initial dose adjustment from the standard adult dose is officially required.

If a dose is missed, standard protocols suggest taking it as soon as remembered unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped to prevent taking two doses simultaneously. These guidelines establish the standardized approach to Gastronal's use.

Recent Clinical Evidence

Recent Clinical Evidence Overview

Clinical research on Gastronal has explored its effect in patients diagnosed with gastrointestinal motility disorders, specifically focusing on symptoms related to delayed gastric emptying. Studies have investigated whether the compound, a prokinetic agent, is associated with changes in the frequency and severity of symptoms such as nausea, vomiting, and feelings of fullness after eating.

Efficacy and Study Endpoints

Phase 3 randomized controlled trials (RCTs) assessed changes in objective measures of gastric function, such as the time it takes for food to pass from the stomach into the small intestine, typically measured using scintigraphy or a breath test. Primary efficacy endpoints in these studies focused on a statistically significant acceleration of gastric emptying time compared to placebo. Secondary endpoints included patient-reported outcome measures (PROs) related to the overall quality of life and the weekly frequency of core symptoms.

Safety and Tolerability

The safety profile of the compound was monitored throughout the clinical development program. Common adverse events reported in the trials generally included headache, diarrhea, and fatigue. No new, unexpected safety signals have been reported in the post-market surveillance or recent large-scale observational studies. Researchers continue to analyze the long-term data from extension studies to fully characterize the sustained safety and tolerability profile across different patient populations.

Key Studies & References

Frequently Asked Questions (FAQ)

Research evidence / Overview of studies for Gastronal

Gastronal for Indication 1: Functional Dyspepsia

Research into the use of Gastronal for Functional Dyspepsia (sometimes called recurring indigestion with no known cause) has primarily involved randomized controlled trials. This type of study often assigns participants randomly to groups receiving the treatment or a comparison (placebo). Participants are assigned to receive either Gastronal or a comparison treatment (like a placebo or another standard therapy).

These studies generally explored whether Gastronal was associated with changes in some of the common and bothersome symptoms of functional dyspepsia, such as feelings of fullness, bloating, and discomfort in the upper stomach area. A number of studies observed differences in the self-reported frequency of symptom changes among participants taking Gastronal compared to those taking a placebo, particularly when looking at overall quality of life related to digestive issues. However, the exact extent of this potential change varied somewhat across different research groups, with some studies reporting a more modest change than others.

It is important to note that while the studies covered a broad range of adult patients with functional dyspepsia, there is limited specific research focusing on how Gastronal performs in certain special groups, such as elderly patients over the age of 75 or people with co-existing long-term health conditions. Also, many of the existing trials followed participants for a relatively short time, typically around four to eight weeks. This means that the long-term effects of use beyond a few months are less clearly understood, and further research is needed to evaluate whether these initial findings are maintained over many months or years.

Gastronal for Indication 2: Irritable Bowel Syndrome with Constipation (IBS-C)

The investigation of Gastronal for Irritable Bowel Syndrome with Constipation (IBS-C) has also relied mainly on randomized, placebo-controlled trials. These studies aimed to assess whether Gastronal was associated with an improvement in core IBS-C symptoms, specifically focusing on bowel movement frequency, stool consistency, and abdominal discomfort.

Findings from this research explored whether participants who received Gastronal reported higher numbers of complete spontaneous bowel movements for people with IBS-C, and the research also examined whether its use was linked to changes in stool consistency. Some participants in the Gastronal group also reported differences in the severity of their abdominal pain compared to those who received a placebo. However, for a significant number of participants, the difference in reported symptom changes between the Gastronal group and the placebo group was relatively small; the findings suggest that the observed outcomes may vary significantly between individuals. The studies indicated that the overall change in symptoms was moderate and inconsistent.

One limitation in the existing evidence base is the inconsistency in how research defined a "successful responder"—meaning there isn't a single, universally accepted measure of what constitutes meaningful change for all people with IBS-C taking Gastronal. Furthermore, most studies have focused on the general adult population, meaning the evidence base is relatively sparse regarding how Gastronal might perform in adolescents (individuals under 18) who also experience IBS-C symptoms. Further research is still needed to clarify the findings of Gastronal across different definitions of success and within younger patient populations.

How should Gastronal be stored and disposed of?

How to Store and Dispose of Gastronal?

This section outlines the official, regulated storage and disposal requirements for Gastronal, based strictly on government-approved labeling.

Official Storage Requirements

Condition	Regulatory Mandate
Temperature	Store at a controlled room temperature; do not exceed 25 C or 30 C.
Environment	Keep the medicine protected from moisture, humidity, and direct light. Do not refrigerate or freeze.
Packaging	Keep the film-coated capsules in the original blister pack or container with the lid tightly closed (if applicable).
Safety	The product must be stored out of the sight and reach of children.

Official Disposal Instructions

Unused or expired Gastronal must be disposed of according to official local regulations. It is a mandatory requirement that the medicine not be flushed down a toilet or discarded into the wastewater system. Disposal should occur via an authorized drug take-back program or pharmacy collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Russia

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z